## Letter to the Editor

## **Medical Principles** and Practice

Received: January 13, 2014 Accepted: March 19, 2014 Published online: April 25, 2014

Med Princ Pract 2014;23:485 DOI: 10.1159/000362338

### **Comment on the Paper Entitled 'Erythropoietin** Ameliorates Oxidative Stress and Tissue Injury following Renal Ischemia/Reperfusion in Rat Kidney and Lung'

Mustafa Aydin<sup>a</sup>, Nilay Hakan<sup>b</sup>, Ugur Deveci<sup>a</sup>, Aysegul Zenciroglu<sup>c</sup>, Nurullah Okumus<sup>c</sup>

<sup>a</sup>Division of Neonatology, Department of Pediatrics, Elazig Training and Research Hospital, Elazig, <sup>b</sup>Division of Neonatology, Department of Pediatrics, Erzurum Training and Research Hospital, Erzurum, and <sup>c</sup>Division of Neonatology, Department of Pediatrics, Dr. Sami Ulus Maternity and Children's Hospital, Ankara, Turkey

### Dear Editor,

We read with great interest the article by Ardalan et al. [1] that reported favorable effects of erythropoietin (Epo) on oxidative stress and tissue injury following renal ischemia/reperfusion in the rat kidney and lung. It is worth pointing out that the positive influence of Epo on cerebral injuries following perinatal asphyxia in newborns has also been shown [2]. Therefore, we would like to emphasize the clinical importance of Epo use in the treatment of patients with neonatal hypoxic ischemic encephalopathy.

Epo is a cytokine hormone with neuroprotective effects that decreases apoptosis, inflammation, and oxidative injury and promotes glial cell survival, angiogenesis, and neurogenesis [3]. Epo is reported to stimulate vascular endothelial growth factor secretion and angiogenesis via the PI3K/Akt and extracellular-signal-regulated kinase (ERK, also known as MAPK) signaling pathways. Other Epo effects are thought to be mediated through the Epo stimulation of brain-derived neurotrophic factor [4, 5]. McPherson and Juul [4] speculated that Epo neuroprotection includes systemic effects such as enhanced erythropoiesis, which increases the stabilization of oxygen availability and iron utilization, thereby decreasing the free iron and reducing the oxidative brain injury. Thus, it improves the long-term brain healing after an insult by providing an increased oxygen-carrying capacity through erythropoiesis and angiogenesis and by increasing neurogenesis. The net effect of the acute actions of Epo is a decrease in apoptosis. Schelshorn et al. [5] found that neurons could specifically express hemoglobin in response to either hypoxia or Epo, and that neuronal hemoglobin expression may be neuroprotective by facilitating oxygen uptake in neurons and serving as an oxygen capacitator molecule. Furthermore, it has been demonstrated that the combined use of hypothermia and Epo has more expressed neuroprotective effects than the sole use of hypothermia after perinatal asphyxia in newborns [3].

We therefore recommend that Epo be included in the treatment guidelines as an adjunctive therapy to therapeutic hypothermia for neuroprotection following a hypoxic-ischemic insult in newborn infants.

#### References

- 1 Ardalan MR, Estakhri R, Hajipour B, et al: Erythropoietin ameliorates oxidative stress and tissue injury following renal ischemia/reperfusion in rat kidney and lung. Med Princ Pract 2013;22:70-74.
- 2 Avasiloaiei A, Dimitriu C, Moscalu M, et al: High-dose phenobarbital or erythropoietin for the treatment of perinatal asphyxia in term newborns. Pediatr Int 2013;55:589-593.
- 3 Traudt CM, McPherson RJ, Bauer LA, et al: Concurrent erythropoietin and hypothermia treatment improve outcomes in a term nonhuman primate model of perinatal asphyxia. Dev Neurosci 2013;35:491-503.
- 4 McPherson RJ, Juul SE: Erythropoietin for infants with hypoxic-ischemic encephalopathy. Curr Opin Pediatr 2010;22:139-145.
- 5 Schelshorn DW, Schneider A, Kuschinsky W, et al: Expression of hemoglobin in rodent neurons. J Cereb Blood Flow Metab 2009;29:585-595.

Editor's Note: The authors of the paper 'Erythropoietin Ameliorates Oxidative Stress and Tissue Injury following Renal Ischemia/Reperfusion in Rat Kidney and Lung' were invited to respond to this letter, but no response was received from them.

# KARGER

E-Mail karger@karger.com www.karger.com/mpp

© 2014 S. Karger AG, Basel 1011-7571/14/0235-0485\$39.50/0

This is an Open Access article licensed under the terms of the

Creative Commons Attribution-NonCommercial 3.0 Un-

ported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Distribution permitted for non-commercial purposes only.



Mustafa Avdin, MD Division of Neonatology, Department of Pediatrics, Elazig Training and Research Hospital Rızaiye Mah. İnönü Cad. No. 74 TR-23000 Elazig (Turkey)

E-Mail dr1mustafa@hotmail.com